Sensory dysfunctions after topical application of cytostatics: A new model for the study of peripheral neuropathies

International Journal of Neuroprotection and Neuroregeneration

Volumn 3, Issue 1, 2006, Pages 32-37

  Wilson, Kerrie ^a,b   Geenen, Frank ^a   Biermans, Ria ^a   Nuydens, Rony ^a   Meert, Theo F ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cisplatin; NGF; Paclitaxel; Pain; Peripheral neuropathy; Vincristine

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; NERVE GROWTH FACTOR; PACLITAXEL; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRICK TEST; RAT; SENSORY DYSFUNCTION;

EID: 34548503605     PISSN: 17451183     EISSN: 17451191     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zimmermann M. Pathobiology of neuropathic pain. European Journal of Pharmacology 2001; 429, 23-37.
2. Kinloch R.A, Cox PJ. New targets for neuropathic pain therapeutics. Expert Opin. Ther. Targets, 2005; 9(4): 685-698.
3. Mc Keage M.J, Haddad G.G, Ding L, Galettis P, Screnci D, Zhuang L, Baguley B.C. Neuroprotective interactions in rats between paclitaxel and cisplatin. Oncology Research, 1999; 11(6):287-93.
4. Himes R.H, Kersey R.N, Heller-Betinger I, Samson F.E. Action of vinca-alkaloids vincristine, vinblastine and desacetyl vinblastine amide on microtubules in vitro. Cancer Research, 1976; 36: 3798-3802.
5. Chazard M, Pellae-Cosset B, Garet F, Soares J.A, Lucidi B, Lavail Y, Lenaz L, Pelaae-Cosset B, Garet F. Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes. Bulletin du Cancer; 1994; 81 (3):173-81.
6. Huang H, Zhu L, Reid B.R, Drobny G.P. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science, 1995; 270: 1842-1845.
7. Cavaletti G and Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opin. Drug Saf., 2004; 3(6):535-546.
8. Bardos G, Moricz K, Jaszlits L, Rabloczky G, Tory K, Racz I, Bernath S, Sumegi B, Farkas B, Literati-Nagy B and Literati-Nagy P. BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats. Toxicology and Applied Pharmacology, 2003; 190, 9-16.
9. Tanner K.D, Reichling D.B and Levine J.B. Nociceptor hyper responsiveness during vincristine induced painful neuropathy in the rat. Journal of Neuroscience, 1998; 18(16): 6480-6491.
10. Ren K, Thomas D.A, Dubner R. Nerve growth factor alleviates a painful peripheral neuropathy in rats. Brain Research, 1995; 699: 286-292.
11. Cavaletti G, Tredici G, Petruccioli M.G, Donde E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Griffon Etienne G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. European Journal of Cancer, 2001; 37: 2457-2463.
12. Pisano C, Pratesi G, Laccabue G, Zunino F, Lo Giudice P, Belluci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P and Cavaletti G. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clinical Cancer Research, 2003; 9: 5756-5767.
13. Dougherty P.M, Cata J.P, Cordella J.V, Burton A, Weng H.R. Taxol-induced sensory disturbance is characterised by preferential impairment of myelinated fiber function in cancer patients. Pain, 2004; 109: 132-142.
14. Cavaletti G, Cavaletti E, Oggioni N, Sottani C, Minoia C, D'Incalci M, Zucchetti M, Marmiroli P, Tredici G. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology, 2000; 21 (3): 389-393.
15. McDonald E.S, Randon K.R, Knight A, Windebank A.J. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiology of Disease, 2005; 18(2): 305-313.
16. Tanner K.D, Reichling D.B, Gear R.W, Paul S.M, Levine J.D. Altered temporal pattern of evoked afferent activity in a rat model of vincristine-induced painful peripheral neuropathy. Neuroscience, 2003; 118: 809-817.
17. Lauria G, Lombardi R, Borgna M, Penza P, Bianchi R, Savino C, Canta A, Nicolini G, Marmiroli P, Cavaletti G. Intraepidermal nerve fibre density in rat food pad: neuropathologic-neurophysiologic correlation. Journal of the Peripheral Nervous System, 2005; 10 (2): 202-208.
18. Zimmerman M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain, 1983; 16(2):109-10.
19. Apfel S.C. Lipton R.B. Arezzo J.C. Kessler J.A. Nerve growth factor prevents toxic neuropathy in mice. Annals of Neurology, 1991; 29 (1):87-90.
20. Apfel S.C. Arezzo J.C. Lipson L. Kessler J.A. Nerve growth factor prevents experimental cisplatin neuropathy. Annals of Neurology, 1992; 31 (1):76-80.
21. Apfel S.C. Kessler J.A. Neurotrophic factors in the treatment of peripheral neuropathy. Ciba Foundation Symposium, 1996; 196:98-108.
22. Tredici G, Braga M, Nicolini G, Miloso M, Marmiroli P, Schenone A, Nobbio L, Frattola L, Cavaletti G. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Experimental Neurology, 1999; 159(2): 551-8.